Biotech Stock Bubble Debate in 14 Charts

BOSTON (

TheStreet

) -- Checking in on the "Biotech Bubble: Yeah or Nay?" debate:

Before we start, let's agree the biotech sector is still having an unbelievable year.

IBB

data by

YCharts

But biotech stocks have underperformed the broader market in the past month.

IBB

data by

YCharts

Momentum-driven biotech stocks -- mostly small- and mid-cap -- have been hit with some serious selling over the past month. These were some of the sector's highest flyers, but not lately. I'm talking about stocks like:

Celldex Therapeutics

(CLDX)

Scroll to Continue

TheStreet Recommends

MARKETS

HDLOW

Home Depot Stock Gains On $15 Billion Buyback, $1.90 Dividend; Ted Decker Named Chairman

Aug 19, 2022 5:49 AM EDT

MARKETS

BBBYGME

Bed, Bath & Beyond Stock Plummets As Ryan Cohen Nets $60 Billion From Activist Exit

Aug 19, 2022 5:22 AM EDT

MARKETS

^DJI^IN^COMPX

Stocks Lower, Applied Materials, Bed, Bath& Beyond, Deere and Foot Locker In Focus - Five Things To Know

Aug 19, 2022 5:04 AM EDT

:

CLDX

data by

YCharts

Clovis Oncology

(CLVS)

:

^NBI

data by

YCharts

and

Immunomedics

(IMMU)

:

IMMU

data by

YCharts

2013 is shaping up to be a record year for biotech IPOs, but not all of the stellar debuts have staying power.

Bluebird Bio

(BLUE)

:

BLUE

data by

YCharts

Alcobra Pharma

undefined

:

ADHD

data by

YCharts

Onconova Therapeutics

(ONTX)

:

ONTX

data by

YCharts

Stemline Therapeutics

(STML)

:

STML

data by

YCharts

Some biotech IPOs keep moving higher, like...

Receptos

(RCPT)

RCPT

data by

YCharts

and

Ambit BioSciences

(AMBI)

:

AMBI

data by

YCharts

Big-cap biotech stocks are still performing strongly. Is there an investor flight to quality companies like

Gilead Sciences

(GILD)

,

Amgen

(AMGN)

,

Biogen Idec

(BIIB)

and

Celgene

(CELG)

?

GILD

data by

YCharts

It's definitely NOT been a hard-knock life for orphan drug stocks in 2013:

AEGR

data by

YCharts

But investors have sent orphans begging in the past month:

AEGR

data by

YCharts

-- Reported by Adam Feuerstein in Boston.

Follow @AdamFeuerstein

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.